Xeris Biopharma Holdings Inc (XERS) concluded trading on 12/21/23 at a closing price of $2.10, with 2.25 million shares of worth about $4.73 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -28.33% during that period and on Thursday the price saw a gain of about 4.48%. Currently the company’s common shares owned by public are about 136.27M shares, out of which, 129.49M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 18 times over the past 12 months. They bought 3,286,139 shares in 18 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Xeris Biopharma Holdings Inc (NASDAQ: XERS) started trading at $2.08, above $0.07 from concluding price of the previous day. However, the stock later moved at a day high price of 2.1800, or with a gain of 4.48%. Stock saw a price change of -3.67% in past 5 days and over the past one month there was a price change of 20.69%. Year-to-date (YTD), XERS shares are showing a performance of 57.89% which increased to 64.06% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.97 but also hit the highest price of $3.07 during that period. The average intraday trading volume for Xeris Biopharma Holdings Inc shares is 1.24 million. The stock is currently trading 8.35% above its 20-day simple moving average (SMA20), while that difference is up 15.47% for SMA50 and it goes to -2.05% lower than SMA200.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) currently have 136.27M outstanding shares and institutions hold larger chunk of about 39.20% of that.
The stock has a current market capitalization of $290.05M and its 3Y-monthly beta is at 1.43. It has posted earnings per share of -$0.45 in the same period. It has Quick Ratio of 1.38 while making debt-to-equity ratio of 58.90. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for XERS, volatility over the week remained 6.77% while standing at 7.26% over the month.
Analysts are in expectations that Xeris Biopharma Holdings Inc (XERS) stock would likely to be making an EPS of -$0.1 in the current quarter, while forecast for next quarter EPS is -$0.09 and it is -$0.29 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.13 which is -$0.07 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.1 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 44.00% while it is estimated to increase by 37.34% in next year.
Analysts at 5 brokerage firms have issued recommendations for the Xeris Biopharma Holdings Inc (XERS)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 5 Wall Street analysts, 5 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Craig Hallum on August 28, 2023 offering a Buy rating for the stock and assigned a target price of $4.50 to it.
